Targeting BRG1 to Improve Drug Efficacy in Neuroblastoma
PublicDownloadable Content
open in viewerMultiple Drug Resistance is one of the main challenges researchers face when developing effective chemotherapy drugs in most cancers. Recent studies have shown that in neuroblastoma, BRG1 gene is active as a pro-oncogenic factor and reducing BRG1 levels by short hairpin RNA decreased neuroblastoma cell proliferation. In a previous study, BRG1 was shown to regulate drug transporter gene expression in response to chemotherapy drug treatment in triple negative breast cancer cells. In this study, we explored the relationship between BRG1 and drug transporters to elucidate the effect of BRG1 silencing on drug resistant neuroblastoma cells treated with chemotherapy drugs. The results support the hypothesis that targeting BRG1 may increase chemo sensitivity in drug resistant neuroblastoma cells.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Creator
- Contributors
- Publisher
- Identifier
- E-project-042518-124038
- Advisor
- Year
- 2018
- Sponsor
- Date created
- 2018-04-25
- Resource type
- Major
- Rights statement
Relations
- In Collection:
Items
Items
Thumbnail | Title | Visibility | Embargo Release Date | Actions |
---|---|---|---|---|
Targeting_BRG1-_Naomi_Otoo.pdf | Public | Download |
Permanent link to this page: https://digital.wpi.edu/show/9306t085s